Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Regulatory
  • UAE approves AstraZeneca’s Baxfendy for hypertension
  • Regulatory

UAE approves AstraZeneca’s Baxfendy for hypertension

Pharmaceutical Technology

AstraZeneca has received approval from the EDE in the UAE for Baxfendy, a medicine using the active ingredient baxdrostat, for uncontrolled hypertension.

Cardiovascular

Read full story

pharminent May 13, 2026 (Last updated: May 16, 2026)

Pharmaceutical Technology

AstraZeneca has received approval from the EDE in the UAE for Baxfendy, a medicine using the active ingredient baxdrostat, for uncontrolled hypertension.

Cardiovascular

Read full story

Post navigation

Previous: Novo, Lilly trade oral GLP-1 data readouts at ECO
Next: Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial

Related Stories

  • Regulatory

Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion

pharminent September 10, 2026
  • Regulatory

HHS appoints permanent FDA CBER, CDER heads

pharminent September 10, 2026
  • Regulatory

FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer

pharminent September 7, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.